Loading
A phase 1/2 trial of Oxaliplatin, Capecitabine and Leucovorin (folinic acid) in advanced solid tumours, run by Zhejiang Doer Biologics Co., Ltd., now recruiting.
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer is a phase 1/2 interventional study registered as NCT07056777 by Zhejiang Doer Biologics Co., Ltd., with 186 participants planned, started 2025-03-25 and due to reach its primary completion in 2027-04-30. Interventions recorded: DR30206, Oxaliplatin, Capecitabine, Calcium Folinate, 5-FU and Irinotecan (CPT-11).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Leucovorin (folinic acid), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/